English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Despite years of intense research, malaria remains a deadly infectious disease worldwide. According to World Health Organization (WHO), Malaria is the fourth most widespread infectious disease after tuberculosis, HIV and pneumonia (Gupta and Guin, 2010). The development of resistance by malaria parasite to the first line and second line antimalarial drugs, has contributed to the persistence of this infectious disease and hence there is an urgent need of new drugs with more safety and efficacy to overcome the burden. Currently artemisinin-based combination treatments are the mainstay of treatment for malaria globally, but P. falciparum emergence of artemisinin resistance in Southeast Asia poses a serious threat to the global control of malaria P. falciparum (WHO, 2016). Therefore, need of identification of an  antimalarial drug that is easy to produce/isolate, is inexpensive, and demonstrates little toxicity across a diverse population is very much important for global malaria control programs and eradication of this deadly infectious disease. Drug discovery for malaria is a time consuming and expensive process, but continuous evolution of the drug discovery methods and high-quality lead generation process is likely to deliver potential compounds with better therapeutic activity. Numerous reports are available  In vitro antimalarial evaluation and molecular docking analysis of Mannich base curcumin analogues against the artemisinin target PfATP6 Kabita Gogoi , Dipak Chetia , Nabin Chandra Barua , Neelutpal Gogoi , Chandrajit Dohutia * 1 2 3 2 4